Investors speak with AstraZeneca on COVID-19 vaccine

Shareholder advocacy |

Praxis joins discussion on equitable allocation and distribution strategy

In December, Praxis joined with other investors to speak with AstraZeneca about the rollout of its COVID-19 vaccine. The investor group was keen to converse with the company about a variety of issues.

Dialogue topics included:

  • Safety and effectiveness – AstraZeneca outlined steps it is taking to prioritize safety and effectiveness, and provided updates on its global trials and efforts to overcome vaccine hesitancy.
  • Global access – AstraZeneca shared its strategy for equitably allocating vaccines with a limited supply, and how it approaches bilateral agreements with various countries.
  • Pricing strategy post-pandemic – AstraZeneca has committed to a “no-profit” approach to its vaccine during the pandemic; discussion was on pricing strategies and affordability once health authorities declare the pandemic is over.
  • Licensing and knowledge sharing – AstraZeneca is taking a more global approach than many other vaccine developers; the company shared its strategy to licensing and regional manufacturing and distribution.

It was a positive dialogue and increased understanding for both the company and investor group. Investors will continue to monitor AstraZeneca and other vaccine makers, with the goal of encouraging a vaccine that’s safe and effective, affordable, and equitably distributed around the world.

Shareholder Advocacy
As a shareholder in AstraZeneca through the Praxis International Index Fund, Praxis engages directly with companies and encourages them to pursue business practices that support positive social change.

Chris Meyer, Stewardship Investing Research and Advocacy Manager | Praxis Mutual Funds
Author Chris Meyer
Manager of Stewardship Investing Research and Advocacy

Shareholder Advocacy in Action

At Praxis, our investments generate a competitive financial return and deliver a clear and direct benefit to people and our planet. We believe it is our responsibility to encourage companies toward responsible business behavior.



As of Dec. 31, 2020, the Praxis International Index Fund has invested 0.66% of its assets in AstraZeneca. Fund holdings are subject to change. To obtain holdings as of the most previous quarter, visit